Mesoblast has provided new analyses from the DREAM-HF Phase III trial showing that the greatest treatment benefit from rexlemestrocel-L is in heart failure and 7 December 2021
Swiss pharma giant Novartis is confident that its sales total will grow by at least 4% at a compound annual growth rate (CAGR) through 2026, investors were told 3 December 2021
The Institute for Clinical and Economic Review (ICER), best known for its cost-effectiveness analyses of innovative drugs and biologics, has published a report 2 December 2021
The Institute for Clinical and Economic Review (ICER) has published a Final Evidence Report assessing the comparative clinical effectiveness and value of mavaca 17 November 2021
While injectable PCSK9 inhibitors have long promised an effective way to lower LDL cholesterol levels, relatively low uptake has been blamed on high prices and 16 November 2021
German life sciences major Bayer was trading 2% higher late on Tuesday after presenting its financial results for the third quarter of 2021. 9 November 2021
After years of questions about the future of its generics and biosimilars business Sandoz, Swiss pharma giant Novartis has finally announced a strategic review 26 October 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.